In this context, we use a novel MNK/VEGFR2 dual inhibitor named JDB153 and provide available data to demonstrate its antitumor effect in combination with chemotherapy or immunotherapy, with the aim to aid feasible optimization for NSCLC treatment. The gene discussed is ATP7A; the disease is non-small cell lung carcinoma.